Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses.
Adult
BNT162 Vaccine
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
COVID-19
/ immunology
Cells, Cultured
Female
Humans
Immunity, Humoral
Immunization, Secondary
Interferon-gamma
/ metabolism
Interleukin-2
/ metabolism
Male
Middle Aged
SARS-CoV-2
/ physiology
Vaccination
Vaccination Hesitancy
Journal
Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
10
11
2021
accepted:
20
12
2021
pubmed:
5
2
2022
medline:
16
3
2022
entrez:
4
2
2022
Statut:
ppublish
Résumé
Delayed dosing intervals are a strategy to immunize a greater proportion of the population. In an observational study, we compared humoral and cellular responses in health care workers receiving two doses of BNT162b2 (Pfizer-BioNTech) vaccine at standard (3- to 6-week) and delayed (8- to 16-week) intervals. In the delayed-interval group, anti-receptor-binding domain antibody titers were significantly enhanced compared to the standard-interval group. The 50% plaque reduction neutralization test (PRNT50) and PRNT90 titers against wild-type (ancestral) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Alpha, Beta and Delta variants were higher in the delayed-interval group. Spike-specific polyfunctional CD4
Identifiants
pubmed: 35115679
doi: 10.1038/s41590-021-01126-6
pii: 10.1038/s41590-021-01126-6
doi:
Substances chimiques
Interleukin-2
0
Interferon-gamma
82115-62-6
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-385Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med 383, 2603–2615 (2020).
doi: 10.1056/NEJMoa2034577
Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881–891 (2021).
doi: 10.1016/S0140-6736(21)00432-3
Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699–5714 (2021).
doi: 10.1016/j.cell.2021.10.011
Robertson, J. F. R., Sewell, H. F. & Stewart, M. Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture? Lancet 397, 879–880 (2021).
doi: 10.1016/S0140-6736(21)00455-4
Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371, eabf4063 (2021).
doi: 10.1126/science.abf4063
Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639–644 (2021).
doi: 10.1038/s41586-021-03207-w
Lederer, K. et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. Immunity 53, 1281–1295 (2020).
doi: 10.1016/j.immuni.2020.11.009
Macallan, D. C., Borghans, J. A. & Asquith, B. Human T cell memory: a dynamic view. Vaccines (Basel) 5, 877 (2017).
Demonbreun, A. R. et al. COVID-19 mRNA vaccination generates greater immunoglobulin G levels in women compared to men. J. Infect. Dis. 224, 793–797 (2021).
doi: 10.1093/infdis/jiab314
Skowronski, D.M., et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. Preprint at medRxiv https://doi.org/10.1101/2021.10.26.21265397 (2021).
Mendoza, E. J., Manguiat, K., Wood, H. & Drebot, M. Two detailed plaque assay protocols for the quantification of infectious SARS-CoV-2. Curr. Protoc. Microbiol 57, ecpmc105 (2020).
doi: 10.1002/cpmc.105
Valcourt, E. J. et al. Evaluating humoral immunity against SARS-CoV-2: validation of a plaque-reduction neutralization test and a multilaboratory comparison of conventional and surrogate neutralization assays. Microbiol. Spectr. 9, e0088621 (2021).
doi: 10.1128/Spectrum.00886-21
Hall, V. G. et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. Am. J. Transpl. 21, 3980–3989 (2021).
doi: 10.1111/ajt.16766
Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (U.S. Food and Drug Administration, 2007).